Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
2
×
boston blog main
life sciences
ally bridge group
big data analytics
bioinnovation capital
biolabs
blackrock
boston top stories
casdin capital
chemotherapy
clinical trials
daraprim
diabetic nephropathy
drug pricing
drugs
epipen
epipens
eventide asset management
exome
focal segmental glomerulosclerosis
gene therapy
generic drugs
goldfinch bio
insulin
irving investors
jay ghosh
johannes fruehauf
labcentral
life science
martin shkreli
mylan
national blog main
national top stories
national xcon
novartis
oncology
peter kolchinsky
price collusion
What
biotech
2
×
drug
2
×
analysis
bio
bring
company
develop
diseases
driving
employing
genetic
goldfinch
good
healthcare
history
improved
industry
innovation
innovations
investment
ipo
kidney
later
lead
life
long
medical
medicines
million
new
outcomes
pricing
proud
public
raised
raises
sciences
studies
wide
Language
unset
Current search:
biotech
×
boston
×
drug
×
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
